Table 1

Expression of IMP3 in patients with lung adenocarcinoma
Variable N IMP3 (Nā€‰=ā€‰90) P
Negative N (%) Positive N (%)
Gradus 1 18 8 (29.6) 10 (15) 0.287
2 23 7 (25.9) 16 (25)
3 49 12 (44) 37 (58)
Subtype solid 52 9 (33) 43 (68) 0.002
others 38 18 (66) 20 (31)
Napsin A negative/light 60 12 (46) 48 (77) 0.004
strong positive 28 14 (53) 14 (22)
TTF-1 negative 31 9 (33.3) 22 (39.2) 0.599
positive 52 18 (66.6) 34 (60.7)
Pleural effusion no 29 6 (42.8) 3 (76.6) 0.063
yes 15 8 (16.6) 7 (23.3)
T staging 2 10 4 (33.3) 6 (21.4) 0.458
3 10 2 (16.6) 8 (28.5)
4 20 6 (50) 14 (50)
N staging 1 20 9 (64) 11 (52.3) 0.612
2 14 5 (35) 9 (42.8)
3 1 0 1 (4)
M staging 0 31 10 (37) 22 (34.9) 0.033
1a 14 8 (29.6) 6 (9.5)
1b 45 9 (33.3) 36 (55.5)

Ļ‡2 test.

Beljan Perak et al.

Beljan Perak et al. Diagnostic Pathology 2012 7:165   doi:10.1186/1746-1596-7-165

Open Data